>Marché mondial des vaccins de voyage, par composition (vaccins combinés et monovaccins), type (vaccins inactivés, vaccins sous-unitaires, recombinants, polysaccharidiques et conjugués, vaccins vivants atténués, vaccins toxoïdes, vaccins à ADN et vaccins à vecteur viral), catégorie (vaccin recommandé, vaccin de routine et vaccin requis), maladie (typhoïde, hépatite, choléra, varicelle, grippe, encéphalite japonaise, méningite à méningocoque, fièvre jaune, rage, DTC, rougeole et oreillons, encéphalite à tiques, paludisme, Covid-19, polio et autres), voie d'administration (injectable et orale), sexe (homme et femme), type de patient (adulte, pédiatrique et gériatrique), tranche d'âge (20-50 ans, moins de 20 ans et plus de 50 ans), canal de distribution (B2B et B2C) - Tendances et prévisions de l'industrie 2032.
Analyse et perspectives du marché des vaccins de voyage
Avec la mondialisation et l’accès facilité aux voyages, de plus en plus de personnes voyagent vers des destinations du monde entier. Cette activité de voyage accrue entraîne une plus grande exposition aux maladies infectieuses répandues dans différentes régions, ce qui stimule la demande de vaccins de voyage pour protéger les individus contre la contraction de maladies comme la fièvre jaune, la typhoïde, l’hépatite A et d’autres. Cependant, l’un des principaux obstacles aux vaccins de voyage est le coût et l’accessibilité. Les vaccins de voyage peuvent être coûteux, en particulier pour les personnes qui peuvent voyager vers plusieurs destinations nécessitant des vaccins différents. De plus, l’accès aux services de santé et aux cliniques de vaccination peut être limité dans certaines régions, ce qui rend difficile pour les voyageurs de recevoir les vaccins nécessaires avant leur voyage. Les progrès de la technologie des vaccins, tels que le développement de nouvelles méthodes d’administration ou de processus de fabrication plus efficaces, offrent des opportunités d’améliorer l’efficacité, l’accessibilité et le caractère abordable des vaccins de voyage. Des innovations telles que les vaccins à ADN, les vaccins à ARNm ou les patchs à micro-aiguilles pourraient potentiellement améliorer le développement et la distribution des vaccins de voyage, les rendant plus largement disponibles et rentables. Cependant, l’hésitation à se faire vacciner et la désinformation posent des défis importants pour les vaccins de voyage. Certaines personnes peuvent être réticentes à se faire vacciner en raison de préoccupations concernant la sécurité, l’efficacité ou d’idées fausses sur les maladies contre lesquelles elles protègent. Il est essentiel de lutter contre l’hésitation à se faire vacciner et de lutter contre la désinformation par le biais de campagnes d’éducation, de sensibilisation et de communication afin de garantir que les voyageurs comprennent l’importance des vaccins pour protéger leur santé et prévenir la propagation des maladies infectieuses au-delà des frontières.
Data Bridge Market Research analyse que le marché mondial des vaccins de voyage devrait atteindre 13,09 milliards USD d'ici 2032, contre 6,14 milliards USD en 2023, avec un TCAC substantiel de 8,9 % au cours de la période de prévision de 2024 à 2032.
|
Rapport métrique |
Détails |
|
Période de prévision |
2024 à 2032 |
|
Année de base |
2023 |
|
Années historiques |
2022 (personnalisable pour 2016-2021) |
|
Unités quantitatives |
Chiffre d'affaires en milliards USD |
|
Segments Covered |
Composition (Combination Vaccines and Mono Vaccines), Type (Inactivated Vaccines, Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, DNA Vaccines, and Viral Vector Vaccines), Category (Recommended Vaccine, Routine Vaccine, and Required Vaccine), Disease (Typhoid, Hepatitis, Cholera, Varicella, Influenza, Japanese Encephalitis, Meningococcal Meningitis, Yellow Fever, Rabies, DPT, Measles and Mumps, Tick-Borne Encephalitis, Malaria, Covid-19, Polio, and Others), Route of Administration (Injectable and Oral), Gender (Male and Female), Patient Type (Adult, Pediatric, and Geriatric), Age Group (20-50 Years, Less than 20 Years, and Above 50 Years), Distribution Channel (B2B and B2C) |
|
Countries Covered |
U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Poland, Norway, Hungary, Austria, Ireland, Lithuania, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, Kuwait, and Rest of Middle East and Africa |
|
Market Players Covered |
GSK plc., Bavarian Nordic, Pfizer Inc., Abbott, CSL, AstraZeneca, Sanofi, Merck & Co., Inc., Valneva SE, Johnson & Johnson Services Inc., and Dynavax Technologies, among others |
Market Definition
Travel vaccines are immunizations specifically designed to protect individuals from infectious diseases that they may encounter while traveling to different regions or countries. These vaccines are administered before departure to destinations where there is a risk of exposure to diseases that are not prevalent in the individual's home country or region. The types of vaccines recommended depend on various factors including the traveler’s destination, duration of stay, activities planned, current health status, and any previous immunizations. The goal of travel vaccines is to prevent the extent of infectious diseases and ensure the health and safety of travelers during their journeys.
Global Travel Vaccine Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Incidence of Infectious Diseases
Alors que les maladies infectieuses se propagent ou réapparaissent dans diverses régions du monde, les voyageurs sont confrontés à un risque accru d’exposition à ces agents pathogènes au cours de leurs déplacements. Les voyageurs peuvent entrer en contact avec des agents infectieux par le biais d’interactions avec les populations locales, d’aliments ou d’eau contaminés, de piqûres d’insectes ou d’une exposition à des dangers environnementaux. Le risque accru d’infection souligne l’importance de la vaccination comme mesure préventive pour protéger les voyageurs contre des maladies potentiellement graves ou mortelles. L’incidence croissante des maladies infectieuses stimule la croissance du marché des vaccins de voyage en augmentant le risque pour les voyageurs, en incitant à des exigences de vaccination obligatoire, en répondant aux flambées épidémiques, en promouvant des mesures préventives contre les maladies endémiques et en répondant aux préoccupations mondiales en matière de sécurité sanitaire.
- Réglementations et recommandations gouvernementales concernant la vaccination
De nombreux pays ont mis en place des exigences de vaccination obligatoires pour les voyageurs entrant sur leur territoire. Ces exigences sont souvent basées sur la prévalence de certaines maladies dans des régions spécifiques et visent à éviter l’importation et la propagation de maladies infectieuses. Par exemple, les pays d’Afrique et d’Amérique du Sud peuvent exiger une preuve de vaccination contre la fièvre jaune pour les voyageurs arrivant de régions où la maladie est endémique. De telles obligations créent une demande directe de vaccins de voyage parmi les voyageurs qui doivent se conformer aux réglementations d’entrée .
Les réglementations et recommandations gouvernementales en matière de vaccination jouent donc un rôle essentiel dans la croissance du marché des vaccins de voyage en créant une demande, en sensibilisant et en facilitant l’accès aux services de vaccination pour les voyageurs. Ces efforts sont essentiels pour préserver la santé publique et minimiser le risque de transmission de maladies lors des voyages internationaux.
Opportunité
- Progrès dans la technologie des vaccins
Les nouvelles plateformes vaccinales, telles que les vaccins à ARNm et les vaccins à vecteur viral, offrent de nouvelles opportunités pour le développement de vaccins destinés aux voyageurs. Ces plateformes innovantes permettent de concevoir et de produire rapidement des vaccins contre un large éventail d’agents pathogènes, notamment ceux responsables des maladies liées aux voyages. En exploitant ces nouvelles plateformes vaccinales, les chercheurs peuvent accélérer le développement de vaccins destinés aux voyageurs de nouvelle génération, plus efficaces et offrant une couverture plus large contre de nombreuses maladies.
Les progrès technologiques en matière de vaccins permettent de concevoir des vaccins à immunogénicité renforcée, ce qui se traduit par des réponses immunitaires plus fortes et plus durables. De nouveaux adjuvants, systèmes d’administration et stratégies de conception d’antigènes améliorent l’efficacité des vaccins en stimulant des réponses immunitaires robustes et en induisant une immunité protectrice contre les agents pathogènes ciblés. En améliorant l’efficacité des vaccins, les avancées technologiques augmentent l’efficacité des vaccins de voyage pour prévenir les maladies et réduire le risque d’infection chez les voyageurs.
Contraintes / Défis
- Exigences relatives à la chaîne du froid pour le stockage
L’infrastructure de la chaîne du froid, notamment les équipements de réfrigération, les dispositifs de surveillance de la température et les installations de stockage, est essentielle pour maintenir l’efficacité des vaccins pendant le stockage et le transport. Cependant, de nombreuses régions, en particulier dans les pays à revenu faible ou intermédiaire et les zones reculées, manquent d’infrastructures de chaîne du froid adéquates. L’absence d’électricité fiable, d’installations de réfrigération et de réseaux de transport complique la gestion de la chaîne du froid et compromet les conditions de stockage des vaccins. Par conséquent, la distribution et l’accès aux vaccins peuvent être limités dans les régions où l’infrastructure de la chaîne du froid est inadéquate, ce qui freine la croissance du marché des vaccins destinés aux voyageurs.
Les vaccins doivent être stockés et transportés dans une plage de température spécifique pour éviter toute exposition à la chaleur ou au froid qui pourrait compromettre leur efficacité. Cependant, les fluctuations de température pendant le transport, comme l’exposition à une chaleur extrême ou à des températures glaciales, peuvent endommager les vaccins et les rendre inefficaces. Il peut être difficile de garantir la stabilité de la température et de la surveiller pendant le transport, en particulier dans les régions où les conditions environnementales sont difficiles ou les systèmes de transport peu fiables. Les vaccins sensibles à la température, tels que ceux qui nécessitent un stockage à très basse température, sont confrontés à des défis supplémentaires pour maintenir la stabilité pendant le transport, ce qui complique encore davantage la gestion de la chaîne du froid et limite l’accessibilité aux vaccins.
- Coût élevé des vaccins de voyage
Pour de nombreuses personnes, en particulier celles qui voyagent avec un budget limité ou dans des pays à faible revenu, le coût des vaccins de voyage peut être prohibitif. Les voyageurs peuvent être obligés de payer eux-mêmes les vaccins, car ils ne sont pas toujours couverts par les régimes d’assurance maladie. Le coût cumulé de plusieurs vaccins recommandés pour voyager dans certaines régions peut s’accumuler rapidement, ce qui conduit certains voyageurs à renoncer complètement à la vaccination ou à donner la priorité à d’autres dépenses de voyage plutôt qu’à la vaccination. Par conséquent, le coût élevé des vaccins de voyage peut dissuader certaines personnes de recourir aux services de vaccination, limitant ainsi la croissance du marché des vaccins de voyage.
Le coût élevé des vaccins de voyage accentue les disparités existantes dans l’accès aux services de santé. Les personnes issues de communautés marginalisées ou mal desservies, qui peuvent déjà être confrontées à des contraintes financières pour accéder aux soins de santé, sont affectées de manière disproportionnée par le coût élevé des vaccins de voyage. Cet accès inégal aux services de vaccination peut contribuer à des écarts dans la couverture vaccinale parmi les voyageurs, en particulier parmi ceux issus de milieux à faibles revenus. En conséquence, la croissance du marché des vaccins de voyage peut être entravée par les obstacles à l’accès imposés par le coût élevé des vaccins.
Développements récents
- In March 2024, Pfizer Inc. announced that the European Commission (EC) has granted marketing approval for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumonia in infants, children and adolescents from 6 weeks to less than 18 years of age
- In October 2023, GSK plc. announced that it has reached an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. (Zhifei) to promote GSK's Zhifei vaccine in China for the first three years. Cooperation can be continued with the consent of all parties. Zhifei, China's largest vaccine company, has acquired innovative vaccines from China. By combining the scale and expertise of the two companies, the strategic partnership will significantly expand the availability of Shingrix, supporting rapid expansion of the vaccine to patients and future potential indications
- In October 2022, Merck & Co., Inc., known as MSD outside the United States and Canada, declared today that the European Commission (EC) has approved an expanded indication for VAXNEUVANCE (15-valent pneumococcal conjugate vaccine), which includes active immunization for prevention. For the treatment of invasive disease, pneumonia and acute otitis media affected by Streptococcus pneumoniae (S. pneumoniae) in infants, children and adolescents from 6 weeks to less than 18 years. The approval facilitates the availability of VAXNEUVANCE to this population in all 27 member states of the European Union (EU), as well as in Iceland, Norway and Liechtenstein
- In September 2022, AstraZeneca announces that doses of FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal) are now available in the United States for the 2022-2023 influenza season. FLUMIST QUADRIVALENT, the only Food and Drug Administration (FDA)-approved nasal spray influenza vaccine, is indicated for ages 2 to 49.1 years. According to the 2022-2023 recommendations of the Immunization Practices Advisory Committee (ACIP) from Centers for Disease Control and Prevention (CDC). And the American Academy of Pediatrics (AAP), FLUMIST QUADRIVALENT remains an alternative to flu vaccination in the United States this season. The CDC emphasizes that the most effective protection against seasonal flu is the annual flu vaccine. This approval will help the company to expand their business
- In February 2021, In February, Johnson & Johnson Services Inc. announced that the U.S. Food and Drug Administration (FDA) has delivered Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, established by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This has helped the company to strengthen its product portfolio
Global Travel Vaccine Market Scope
The global travel vaccine market is segmented into nine notable segments which are based on composition, type, category, disease, route of administration, gender, patient type, age group, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Composition
- Combination Vaccines
- Mono Vaccines
On the basis of composition, the market is segmented into combination vaccines and mono vaccines.
Type
- Inactivated Vaccines
- Subunit, Recombinant, Polysaccharide and Conjugate Vaccines
- Live-Attenuated Vaccines
- Toxoid Vaccines
- DNA Vaccines
- Viral Vector Vaccines
On the basis of type, the market is segmented into inactivated vaccines, subunit, recombinant, polysaccharide and conjugate vaccines, live-attenuated vaccines, toxoid vaccines, DNA vaccines, and viral vector vaccines.
Category
- Recommended Vaccine
- Routine Vaccine
- Required Vaccine
On the basis of category, the market is segmented into recommended vaccine, routine vaccine, and required vaccine.
Disease
- Typhoid
- Hepatitis
- Cholera
- Varicella
- Influenza
- Japanese Encephalitis
- Meningococcal Meningitis
- Yellow Fever
- Rabies
- DPT
- Measles and Mumps
- Tick-Borne Encephalitis
- Malaria
- Covid-19
- Polio
- Others
On the basis of disease, the market is segmented into typhoid, hepatitis, cholera, varicella, influenza, Japanese encephalitis, meningococcal meningitis, yellow fever, rabies, DPT, measles and mumps, tick-borne encephalitis, malaria, covid-19, polio, and others.
Route of Administration
- Injectable
- Oral
On the basis of route of administration, the market is segmented into injectable and oral.
Gender
- Male
- Female
On the basis of gender, the market is segmented into male and female.
Patient Type
- Adult
- Pediatric
- Geriatric
On the basis of patient type, the market is segmented into adult, pediatric, and geriatric.
Age Group
- 20-50 Years
- Less than 20 Years
- Above 50 Years
On the basis of age group, the market is segmented into 20-50 years, less than 20 years, and above 50 years.
Distribution Channel
- B2B
- B2C
On the basis of distribution channel, the market is segmented into B2B and B2C.
Global Travel Vaccine Market Regional Analysis/Insights
The global travel vaccine market is segmented into nine notable segments which are based on composition, type, category, disease, route of administration, gender, patient type, age group, and distribution channel.
The countries covered in this market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Poland, Norway, Hungary, Austria, Ireland, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, Kuwait, and rest of Middle East and Africa.
L'Amérique du Nord devrait dominer le marché mondial des vaccins de voyage avec des politiques de remboursement favorables pour le traitement de dialyse. Les États-Unis devraient dominer la région Amérique du Nord en raison de la présence d'acteurs majeurs du marché et de l'amélioration du développement et de la recherche dans le secteur de la santé. L'Inde devrait dominer la région Asie-Pacifique en raison de sa vaste superficie et de son grand bassin de patients gériatriques. L'Allemagne devrait dominer la région Europe en raison de son adoption de technologies avancées, de sa solide infrastructure de soins de santé et de son marché mature.
La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie du pays, les actes réglementaires et les tarifs douaniers d'import-export sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario du marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales et l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché mondiales des vaccins de voyage
Le paysage concurrentiel du marché mondial des vaccins de voyage fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché mondial des vaccins de voyage.
Certains des principaux acteurs du marché opérant sur le marché mondial des vaccins de voyage sont GSK plc., Bavarian Nordic, Pfizer Inc., Abbott, CSL, AstraZeneca, Sanofi, Merck & Co., Inc., Valneva SE, Johnson & Johnson Services Inc. et Dynavax Technologies, entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL TRAVEL VACCINES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PIPELINE ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING INCIDENCE OF INFECTIOUS DISEASES
5.1.2 INCREASING TRAVEL AND TOURISM
5.1.3 GOVERNMENT REGULATIONS AND RECOMMENDATIONS REGARDING VACCINATION
5.1.4 EXPANSION OF TRAVEL MEDICINE CLINICS
5.2 RESTRAINTS
5.2.1 HIGH COST OF TRAVEL VACCINES
5.2.2 REGULATORY HURDLES FOR APPROVAL
5.3 OPPORTUNITIES
5.3.1 ADVANCEMENTS IN VACCINE TECHNOLOGY
5.3.2 GROWING AWARENESS REGARDING VACCINES
5.3.3 INTEGRATION OF DIGITAL HEALTH SOLUTIONS
5.4 CHALLENGES
5.4.1 COLD CHAIN REQUIREMENTS FOR STORAGE
5.4.2 VACCINE HESITANCY AND MISINFORMATION
6 GLOBAL TRAVEL VACCINE MARKET, BY COMPOSITION
6.1 OVERVIEW
6.2 COMBINATION VACCINES
6.3 MONO VACCINES
7 GLOBAL TRAVEL VACCINE MARKET, BY TYPE
7.1 OVERVIEW
7.2 INACTIVATED VACCINES
7.2.1 HEPATITIS A
7.2.2 INFLUENZA
7.2.3 RABIES
7.2.4 TICK-BORNE ENCEPHALITIS
7.2.5 JAPANESE ENCEPHALITIS
7.2.6 POLIO
7.3 SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES
7.3.1 HEPATITIS B
7.3.2 MENINGOCOCCAL
7.3.3 MALARIA
7.3.4 COVID-19
7.4 LIVE-ATTENUATED VACCINES
7.4.1 TYPHOID
7.4.2 CHOLERA
7.4.3 YELLOW FEVER
7.4.4 MEASLES
7.4.5 MUMPS
7.4.6 RUBELLA
7.4.7 VARICELLA
7.4.8 OTHERS
7.5 TOXOID VACCINES
7.5.1 DIPHTHERIA
7.5.2 TETANUS
7.6 DNA VACCINES
7.7 VIRAL VECTOR VACCINES
8 GLOBAL TRAVEL VACCINE MARKET, BY CATEGORY
8.1 OVERVIEW
8.2 RECOMMENDED VACCINE
8.2.1 TYPHOID FEVER VACCINES
8.2.2 HEPATITIS A
8.2.3 CHOLERA
8.2.4 RABIES
8.2.5 TICK-BORNE ENCEPHALITIS
8.2.6 JAPANESE ENCEPHALITIS
8.2.7 MALARIA
8.2.8 OTHERS
8.3 ROUTINE VACCINE
8.3.1 HEPATITIS B
8.3.2 INFLUENZA VACCINES
8.3.3 PNEUMOCOCCAL
8.3.4 DIPHTHERIA
8.3.5 TETANUS
8.3.6 MEASLES
8.3.7 MUMPS
8.3.8 RUBELLA
8.3.9 PERTUSSIS
8.3.10 OTHERS
8.4 REQUIRED VACCINE
8.4.1 YELLOW FEVER
8.4.2 MENINGOCOCCAL
8.4.3 POLIO VACCINES
9 GLOBAL TRAVEL VACCINE MARKET, BY DISEASE
9.1 OVERVIEW
9.2 TYPHOID
9.3 HEPATITIS
9.3.1 HEPATITIS A
9.3.2 HEPATITIS B
9.4 CHOLERA
9.5 VARICELLA
9.6 INFLUENZA
9.7 JAPANESE ENCEPHALITIS
9.8 MENINGOCOCCAL MENINGITIS
9.9 YELLOW FEVER
9.1 RABIES
9.11 DPT
9.12 MEASLES AND MUMPS
9.13 TICK-BORNE ENCEPHALITIS
9.14 MALARIA
9.15 COVID-19
9.16 POLIO
9.17 OTHERS
10 GLOBAL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION
10.1 OVERVIEW
10.2 INJECTABLE
10.2.1 INTRAMUSCULAR
10.2.2 SUBCUTANEOUS
10.2.3 OTHERS
10.3 ORAL
11 GLOBAL TRAVEL VACCINE MARKET, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12 GLOBAL TRAVEL VACCINE MARKET, BY PATIENT TYPE
12.1 OVERVIEW
12.2 ADULT
12.3 PEDIATRIC
12.4 GERIATRIC
13 GLOBAL TRAVEL VACCINE MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 20-50 YEARS
13.3 LESS THAN 20 YEARS
13.4 ABOVE 50 YEARS
14 GLOBAL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 B2B
14.3 B2C
15 GLOBAL TRAVEL VACCINE MARKET, BY REGION
15.1 OVERVIEW
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.2 CANADA
15.2.3 MEXICO
15.3 ASIA-PACIFIC
15.3.1 INDIA
15.3.2 CHINA
15.3.3 MALAYSIA
15.3.4 SOUTH KOREA
15.3.5 JAPAN
15.3.6 AUSTRALIA
15.3.7 THAILAND
15.3.8 VIETNAM
15.3.9 SINGAPORE
15.3.10 INDONESIA
15.3.11 PHILIPPINES
15.3.12 REST OF ASIA-PACIFIC
15.4 EUROPE
15.4.1 GERMANY
15.4.2 U.K.
15.4.3 FRANCE
15.4.4 RUSSIA
15.4.5 ITALY
15.4.6 SPAIN
15.4.7 POLAND
15.4.8 NETHERLANDS
15.4.9 SWITZERLAND
15.4.10 HUNGARY
15.4.11 AUSTRIA
15.4.12 IRELAND
15.4.13 NORWAY
15.4.14 LITHUANIA
15.4.15 REST OF EUROPE
15.5 MIDDLE EAST AND AFRICA
15.5.1 SAUDI ARABIA
15.5.2 EGYPT
15.5.3 SOUTH AFRICA
15.5.4 KUWAIT
15.5.5 U.A.E.
15.5.6 ISRAEL
15.5.7 REST OF MIDDLE EAST AND AFRICA
15.6 SOUTH AMERICA
15.6.1 ARGENTINA
15.6.2 BRAZIL
15.6.3 PERU
15.6.4 REST OF SOUTH AMERICA
16 GLOBAL TRAVEL VACCINE MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: GLOBAL
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
16.3 COMPANY SHARE ANALYSIS: EUROPE
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 SANOFI
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 JOHNSON & JOHNSON SERVICES INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 GSK PLC.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 MERCK & CO., INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 ABBOTT
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 ASTRAZENECA
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 BAVARIAN NORDIC
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENT
18.9 CSL
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 DYNAVAX TECHNOLOGIES.
18.10.1 COMPANY SNAPSHOT
18.10.2 REVENUE ANALYSIS
18.10.3 PRODUCT PORTFOLIO
18.10.4 RECENT DEVELOPMENTS
18.11 VALNEVA SE
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Liste des tableaux
TABLE 1 PIPELINE ANALYSIS OF TRAVEL VACCINES MARKET
TABLE 2 VACCINES RECOMMENDATION FOR INTERNATIONAL TRAVELERS
TABLE 3 GLOBAL TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 4 GLOBAL COMBINATION VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 5 GLOBAL MONO VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 6 GLOBAL TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 7 GLOBAL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 8 GLOBAL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 9 GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 10 GLOBAL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 11 GLOBAL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 12 GLOBAL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 13 GLOBAL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 14 GLOBAL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 15 GLOBAL DNA VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 16 GLOBAL VIRAL VECTOR VACCINES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 17 GLOBAL TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 18 GLOBAL RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 19 GLOBAL RECOMMENDED VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 20 GLOBAL ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 21 GLOBAL ROUTINE VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 22 GLOBAL REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 23 GLOBAL REQUIRED VACCINES IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 24 GLOBAL TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 25 GLOBAL TYPHOID IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 26 GLOBAL HEPATITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 27 GLOBAL HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 28 GLOBAL CHOLERA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 29 GLOBAL VARICELLA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 30 GLOBAL INFLUENZA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 31 GLOBAL JAPANESE ENCEPHALITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 32 GLOBAL MENINGOCOCCAL MENINGITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 33 GLOBAL YELLOW FEVER IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 34 GLOBAL RABIES IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 35 GLOBAL DPT IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 36 GLOBAL MEASLES AND MUMPS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 37 GLOBAL TICK-BORNE ENCEPHALITIS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 38 GLOBAL MALARIA IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 39 GLOBAL COVID-19 IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 40 GLOBAL POLIO IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 41 GLOBAL OTHERS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 42 GLOBAL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 43 GLOBAL INJECTABLE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 44 GLOBAL INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 45 GLOBAL ORAL IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 46 GLOBAL TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 47 GLOBAL MALE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 48 GLOBAL FEMALE IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 49 GLOBAL TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 50 GLOBAL ADULT IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 51 GLOBAL PEDIATRIC IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 52 GLOBAL GERIATRIC IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 53 GLOBAL TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 54 GLOBAL 20-50 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 55 GLOBAL LESS THAN 20 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 56 GLOBAL ABOVE 50 YEARS IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 57 GLOBAL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 58 GLOBAL B2B IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 59 GLOBAL B2C IN TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 60 GLOBAL TRAVEL VACCINE MARKET, BY REGION, 2022-2032 (USD THOUSAND)
TABLE 61 NORTH AMERICA TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)
TABLE 62 NORTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 63 NORTH AMERICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 64 NORTH AMERICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 65 NORTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 66 NORTH AMERICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 67 NORTH AMERICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 68 NORTH AMERICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 69 NORTH AMERICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 70 NORTH AMERICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 71 NORTH AMERICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 72 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 73 NORTH AMERICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 74 NORTH AMERICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 75 NORTH AMERICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 76 NORTH AMERICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 77 NORTH AMERICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 78 NORTH AMERICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 79 NORTH AMERICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 80 U.S. TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 81 U.S. TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 82 U.S. INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 83 U.S. SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 84 U.S. LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 85 U.S. TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 86 U.S. TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 87 U.S. RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 88 U.S. ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 89 U.S. REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 90 U.S. TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 91 U.S. HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 92 U.S. TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 93 U.S. INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 94 U.S. TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 95 U.S. TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 96 U.S. TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 97 U.S. TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 98 CANADA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 99 CANADA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 100 CANADA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 101 CANADA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 102 CANADA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 103 CANADA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 104 CANADA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 105 CANADA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 106 CANADA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 107 CANADA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 108 CANADA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 109 CANADA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 110 CANADA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 111 CANADA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 112 CANADA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 113 CANADA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 114 CANADA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 115 CANADA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 116 MEXICO TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 117 MEXICO TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 118 MEXICO INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 119 MEXICO SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 120 MEXICO LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 121 MEXICO TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 122 MEXICO TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 123 MEXICO RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 124 MEXICO ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 125 MEXICO REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 126 MEXICO TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 127 MEXICO HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 128 MEXICO TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 129 MEXICO INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 130 MEXICO TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 131 MEXICO TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 132 MEXICO TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 133 MEXICO TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 134 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)
TABLE 135 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 136 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 137 ASIA-PACIFIC INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 138 ASIA-PACIFIC SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 139 ASIA-PACIFIC LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 140 ASIA-PACIFIC TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 141 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 142 ASIA-PACIFIC RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 143 ASIA-PACIFIC ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 144 ASIA-PACIFIC REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 145 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 146 ASIA-PACIFIC HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 147 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 148 ASIA-PACIFIC INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 149 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 150 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 151 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 152 ASIA-PACIFIC TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 153 INDIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 154 INDIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 155 INDIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 156 INDIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 157 INDIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 158 INDIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 159 INDIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 160 INDIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 161 INDIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 162 INDIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 163 INDIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 164 INDIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 165 INDIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 166 INDIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 167 INDIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 168 INDIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 169 INDIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 170 INDIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 171 CHINA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 172 CHINA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 173 CHINA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 174 CHINA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 175 CHINA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 176 CHINA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 177 CHINA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 178 CHINA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 179 CHINA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 180 CHINA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 181 CHINA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 182 CHINA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 183 CHINA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 184 CHINA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 185 CHINA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 186 CHINA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 187 CHINA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 188 CHINA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 189 MALAYSIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 190 MALAYSIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 191 MALAYSIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 192 MALAYSIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 193 MALAYSIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 194 MALAYSIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 195 MALAYSIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 196 MALAYSIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 197 MALAYSIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 198 MALAYSIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 199 MALAYSIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 200 MALAYSIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 201 MALAYSIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 202 MALAYSIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 203 MALAYSIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 204 MALAYSIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 205 MALAYSIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 206 MALAYSIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 207 SOUTH KOREA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 208 SOUTH KOREA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 209 SOUTH KOREA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 210 SOUTH KOREA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 211 SOUTH KOREA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 212 SOUTH KOREA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 213 SOUTH KOREA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 214 SOUTH KOREA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 215 SOUTH KOREA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 216 SOUTH KOREA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 217 SOUTH KOREA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 218 SOUTH KOREA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 219 SOUTH KOREA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 220 SOUTH KOREA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 221 SOUTH KOREA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 222 SOUTH KOREA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 223 SOUTH KOREA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 224 SOUTH KOREA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 225 JAPAN TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 226 JAPAN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 227 JAPAN INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 228 JAPAN SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 229 JAPAN LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 230 JAPAN TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 231 JAPAN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 232 JAPAN RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 233 JAPAN ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 234 JAPAN REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 235 JAPAN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 236 JAPAN HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 237 JAPAN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 238 JAPAN INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 239 JAPAN TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 240 JAPAN TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 241 JAPAN TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 242 JAPAN TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 243 AUSTRALIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 244 AUSTRALIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 245 AUSTRALIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 246 AUSTRALIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 247 AUSTRALIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 248 AUSTRALIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 249 AUSTRALIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 250 AUSTRALIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 251 AUSTRALIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 252 AUSTRALIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 253 AUSTRALIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 254 AUSTRALIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 255 AUSTRALIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 256 AUSTRALIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 257 AUSTRALIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 258 AUSTRALIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 259 AUSTRALIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 260 AUSTRALIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 261 THAILAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 262 THAILAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 263 THAILAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 264 THAILAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 265 THAILAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 266 THAILAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 267 THAILAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 268 THAILAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 269 THAILAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 270 THAILAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 271 THAILAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 272 THAILAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 273 THAILAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 274 THAILAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 275 THAILAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 276 THAILAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 277 THAILAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 278 THAILAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 279 VIETNAM TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 280 VIETNAM TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 281 VIETNAM INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 282 VIETNAM SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 283 VIETNAM LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 284 VIETNAM TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 285 VIETNAM TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 286 VIETNAM RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 287 VIETNAM ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 288 VIETNAM REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 289 VIETNAM TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 290 VIETNAM HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 291 VIETNAM TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 292 VIETNAM INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 293 VIETNAM TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 294 VIETNAM TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 295 VIETNAM TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 296 VIETNAM TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 297 SINGAPORE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 298 SINGAPORE TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 299 SINGAPORE INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 300 SINGAPORE SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 301 SINGAPORE LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 302 SINGAPORE TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 303 SINGAPORE TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 304 SINGAPORE RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 305 SINGAPORE ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 306 SINGAPORE REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 307 SINGAPORE TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 308 SINGAPORE HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 309 SINGAPORE TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 310 SINGAPORE INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 311 SINGAPORE TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 312 SINGAPORE TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 313 SINGAPORE TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 314 SINGAPORE TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 315 INDONESIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 316 INDONESIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 317 INDONESIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 318 INDONESIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 319 INDONESIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 320 INDONESIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 321 INDONESIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 322 INDONESIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 323 INDONESIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 324 INDONESIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 325 INDONESIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 326 INDONESIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 327 INDONESIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 328 INDONESIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 329 INDONESIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 330 INDONESIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 331 INDONESIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 332 INDONESIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 333 PHILIPPINES TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 334 PHILIPPINES TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 335 PHILIPPINES INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 336 PHILIPPINES SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 337 PHILIPPINES LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 338 PHILIPPINES TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 339 PHILIPPINES TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 340 PHILIPPINES RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 341 PHILIPPINES ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 342 PHILIPPINES REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 343 PHILIPPINES TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 344 PHILIPPINES HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 345 PHILIPPINES TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 346 PHILIPPINES INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 347 PHILIPPINES TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 348 PHILIPPINES TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 349 PHILIPPINES TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 350 PHILIPPINES TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 351 REST OF ASIA-PACIFIC TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 352 EUROPE TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)
TABLE 353 EUROPE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 354 EUROPE TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 355 EUROPE INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 356 EUROPE SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 357 EUROPE LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 358 EUROPE TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 359 EUROPE TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 360 EUROPE RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 361 EUROPE ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 362 EUROPE REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 363 EUROPE TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 364 EUROPE HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 365 EUROPE TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 366 EUROPE INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 367 EUROPE TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 368 EUROPE TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 369 EUROPE TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 370 EUROPE TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 371 GERMANY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 372 GERMANY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 373 GERMANY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 374 GERMANY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 375 GERMANY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 376 GERMANY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 377 GERMANY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 378 GERMANY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 379 GERMANY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 380 GERMANY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 381 GERMANY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 382 GERMANY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 383 GERMANY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 384 GERMANY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 385 GERMANY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 386 GERMANY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 387 GERMANY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 388 GERMANY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 389 U.K. TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 390 U.K. TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 391 U.K. INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 392 U.K. SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 393 U.K. LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 394 U.K. TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 395 U.K. TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 396 U.K. RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 397 U.K. ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 398 U.K. REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 399 U.K. TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 400 U.K. HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 401 U.K. TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 402 U.K. INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 403 U.K. TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 404 U.K. TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 405 U.K. TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 406 U.K. TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 407 FRANCE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 408 FRANCE TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 409 FRANCE INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 410 FRANCE SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 411 FRANCE LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 412 FRANCE TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 413 FRANCE TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 414 FRANCE RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 415 FRANCE ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 416 FRANCE REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 417 FRANCE TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 418 FRANCE HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 419 FRANCE TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 420 FRANCE INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 421 FRANCE TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 422 FRANCE TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 423 FRANCE TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 424 FRANCE TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 425 RUSSIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 426 RUSSIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 427 RUSSIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 428 RUSSIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 429 RUSSIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 430 RUSSIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 431 RUSSIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 432 RUSSIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 433 RUSSIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 434 RUSSIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 435 RUSSIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 436 RUSSIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 437 RUSSIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 438 RUSSIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 439 RUSSIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 440 RUSSIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 441 RUSSIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 442 RUSSIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 443 ITALY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 444 ITALY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 445 ITALY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 446 ITALY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 447 ITALY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 448 ITALY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 449 ITALY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 450 ITALY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 451 ITALY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 452 ITALY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 453 ITALY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 454 ITALY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 455 ITALY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 456 ITALY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 457 ITALY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 458 ITALY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 459 ITALY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 460 ITALY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 461 SPAIN TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 462 SPAIN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 463 SPAIN INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 464 SPAIN SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 465 SPAIN LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 466 SPAIN TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 467 SPAIN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 468 SPAIN RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 469 SPAIN ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 470 SPAIN REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 471 SPAIN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 472 SPAIN HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 473 SPAIN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 474 SPAIN INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 475 SPAIN TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 476 SPAIN TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 477 SPAIN TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 478 SPAIN TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 479 POLAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 480 POLAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 481 POLAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 482 POLAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 483 POLAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 484 POLAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 485 POLAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 486 POLAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 487 POLAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 488 POLAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 489 POLAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 490 POLAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 491 POLAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 492 POLAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 493 POLAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 494 POLAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 495 POLAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 496 POLAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 497 NETHERLANDS TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 498 NETHERLANDS TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 499 NETHERLANDS INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 500 NETHERLANDS SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 501 NETHERLANDS LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 502 NETHERLANDS TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 503 NETHERLANDS TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 504 NETHERLANDS RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 505 NETHERLANDS ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 506 NETHERLANDS REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 507 NETHERLANDS TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 508 NETHERLANDS HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 509 NETHERLANDS TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 510 NETHERLANDS INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 511 NETHERLANDS TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 512 NETHERLANDS TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 513 NETHERLANDS TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 514 NETHERLANDS TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 515 SWITZERLAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 516 SWITZERLAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 517 SWITZERLAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 518 SWITZERLAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 519 SWITZERLAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 520 SWITZERLAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 521 SWITZERLAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 522 SWITZERLAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 523 SWITZERLAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 524 SWITZERLAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 525 SWITZERLAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 526 SWITZERLAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 527 SWITZERLAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 528 SWITZERLAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 529 SWITZERLAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 530 SWITZERLAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 531 SWITZERLAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 532 SWITZERLAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 533 HUNGARY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 534 HUNGARY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 535 HUNGARY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 536 HUNGARY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 537 HUNGARY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 538 HUNGARY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 539 HUNGARY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 540 HUNGARY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 541 HUNGARY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 542 HUNGARY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 543 HUNGARY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 544 HUNGARY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 545 HUNGARY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 546 HUNGARY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 547 HUNGARY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 548 HUNGARY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 549 HUNGARY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 550 HUNGARY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 551 AUSTRIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 552 AUSTRIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 553 AUSTRIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 554 AUSTRIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 555 AUSTRIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 556 AUSTRIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 557 AUSTRIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 558 AUSTRIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 559 AUSTRIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 560 AUSTRIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 561 AUSTRIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 562 AUSTRIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 563 AUSTRIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 564 AUSTRIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 565 AUSTRIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 566 AUSTRIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 567 AUSTRIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 568 AUSTRIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 569 IRELAND TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 570 IRELAND TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 571 IRELAND INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 572 IRELAND SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 573 IRELAND LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 574 IRELAND TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 575 IRELAND TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 576 IRELAND RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 577 IRELAND ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 578 IRELAND REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 579 IRELAND TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 580 IRELAND HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 581 IRELAND TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 582 IRELAND INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 583 IRELAND TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 584 IRELAND TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 585 IRELAND TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 586 IRELAND TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 587 NORWAY TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 588 NORWAY TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 589 NORWAY INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 590 NORWAY SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 591 NORWAY LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 592 NORWAY TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 593 NORWAY TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 594 NORWAY RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 595 NORWAY ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 596 NORWAY REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 597 NORWAY TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 598 NORWAY HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 599 NORWAY TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 600 NORWAY INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 601 NORWAY TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 602 NORWAY TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 603 NORWAY TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 604 NORWAY TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 605 LITHUANIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 606 LITHUANIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 607 LITHUANIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 608 LITHUANIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 609 LITHUANIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 610 LITHUANIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 611 LITHUANIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 612 LITHUANIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 613 LITHUANIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 614 LITHUANIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 615 LITHUANIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 616 LITHUANIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 617 LITHUANIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 618 LITHUANIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 619 LITHUANIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 620 LITHUANIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 621 LITHUANIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 622 LITHUANIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 623 REST OF EUROPE TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 624 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)
TABLE 625 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 626 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 627 MIDDLE EAST AND AFRICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 628 MIDDLE EAST AND AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 629 MIDDLE EAST AND AFRICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 630 MIDDLE EAST AND AFRICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 631 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 632 MIDDLE EAST AND AFRICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 633 MIDDLE EAST AND AFRICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 634 MIDDLE EAST AND AFRICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 635 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 636 MIDDLE EAST AND AFRICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 637 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 638 MIDDLE EAST AND AFRICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 639 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 640 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 641 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 642 MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 643 SAUDI ARABIA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 644 SAUDI ARABIA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 645 SAUDI ARABIA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 646 SAUDI ARABIA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 647 SAUDI ARABIA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 648 SAUDI ARABIA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 649 SAUDI ARABIA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 650 SAUDI ARABIA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 651 SAUDI ARABIA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 652 SAUDI ARABIA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 653 SAUDI ARABIA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 654 SAUDI ARABIA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 655 SAUDI ARABIA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 656 SAUDI ARABIA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 657 SAUDI ARABIA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 658 SAUDI ARABIA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 659 SAUDI ARABIA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 660 SAUDI ARABIA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 661 EGYPT TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 662 EGYPT TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 663 EGYPT INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 664 EGYPT SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 665 EGYPT LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 666 EGYPT TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 667 EGYPT TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 668 EGYPT RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 669 EGYPT ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 670 EGYPT REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 671 EGYPT TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 672 EGYPT HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 673 EGYPT TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 674 EGYPT INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 675 EGYPT TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 676 EGYPT TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 677 EGYPT TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 678 EGYPT TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 679 SOUTH AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 680 SOUTH AFRICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 681 SOUTH AFRICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 682 SOUTH AFRICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 683 SOUTH AFRICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 684 SOUTH AFRICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 685 SOUTH AFRICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 686 SOUTH AFRICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 687 SOUTH AFRICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 688 SOUTH AFRICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 689 SOUTH AFRICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 690 SOUTH AFRICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 691 SOUTH AFRICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 692 SOUTH AFRICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 693 SOUTH AFRICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 694 SOUTH AFRICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 695 SOUTH AFRICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 696 SOUTH AFRICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 697 KUWAIT TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 698 KUWAIT TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 699 KUWAIT INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 700 KUWAIT SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 701 KUWAIT LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 702 KUWAIT TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 703 KUWAIT TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 704 KUWAIT RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 705 KUWAIT ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 706 KUWAIT REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 707 KUWAIT TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 708 KUWAIT HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 709 KUWAIT TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 710 KUWAIT INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 711 KUWAIT TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 712 KUWAIT TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 713 KUWAIT TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 714 KUWAIT TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 715 U.A.E. TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 716 U.A.E. TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 717 U.A.E. INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 718 U.A.E. SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 719 U.A.E. LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 720 U.A.E. TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 721 U.A.E. TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 722 U.A.E. RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 723 U.A.E. ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 724 U.A.E. REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 725 U.A.E. TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 726 U.A.E. HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 727 U.A.E. TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 728 U.A.E. INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 729 U.A.E. TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 730 U.A.E. TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 731 U.A.E. TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 732 U.A.E. TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 733 ISRAEL TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 734 ISRAEL TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 735 ISRAEL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 736 ISRAEL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 737 ISRAEL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 738 ISRAEL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 739 ISRAEL TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 740 ISRAEL RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 741 ISRAEL ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 742 ISRAEL REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 743 ISRAEL TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 744 ISRAEL HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 745 ISRAEL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 746 ISRAEL INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 747 ISRAEL TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 748 ISRAEL TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 749 ISRAEL TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 750 ISRAEL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 751 REST OF MIDDLE EAST AND AFRICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 752 SOUTH AMERICA TRAVEL VACCINE MARKET, BY COUNTRY, 2022-2032 (USD THOUSAND)
TABLE 753 SOUTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 754 SOUTH AMERICA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 755 SOUTH AMERICA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 756 SOUTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 757 SOUTH AMERICA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 758 SOUTH AMERICA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 759 SOUTH AMERICA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 760 SOUTH AMERICA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 761 SOUTH AMERICA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 762 SOUTH AMERICA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 763 SOUTH AMERICA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 764 SOUTH AMERICA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 765 SOUTH AMERICA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 766 SOUTH AMERICA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 767 SOUTH AMERICA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 768 SOUTH AMERICA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 769 SOUTH AMERICA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 770 SOUTH AMERICA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 771 ARGENTINA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 772 ARGENTINA TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 773 ARGENTINA INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 774 ARGENTINA SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 775 ARGENTINA LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 776 ARGENTINA TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 777 ARGENTINA TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 778 ARGENTINA RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 779 ARGENTINA ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 780 ARGENTINA REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 781 ARGENTINA TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 782 ARGENTINA HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 783 ARGENTINA TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 784 ARGENTINA INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 785 ARGENTINA TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 786 ARGENTINA TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 787 ARGENTINA TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 788 ARGENTINA TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 789 BRAZIL TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 790 BRAZIL TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 791 BRAZIL INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 792 BRAZIL SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 793 BRAZIL LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 794 BRAZIL TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 795 BRAZIL TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 796 BRAZIL RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 797 BRAZIL ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 798 BRAZIL REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 799 BRAZIL TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 800 BRAZIL HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 801 BRAZIL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 802 BRAZIL INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 803 BRAZIL TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 804 BRAZIL TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 805 BRAZIL TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 806 BRAZIL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 807 PERU TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
TABLE 808 PERU TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 809 PERU INACTIVATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 810 PERU SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 811 PERU LIVE-ATTENUATED VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 812 PERU TOXOID VACCINES IN TRAVEL VACCINE MARKET, BY TYPE, 2022-2032 (USD THOUSAND)
TABLE 813 PERU TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 814 PERU RECOMMENDED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 815 PERU ROUTINE VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 816 PERU REQUIRED VACCINE IN TRAVEL VACCINE MARKET, BY CATEGORY, 2022-2032 (USD THOUSAND)
TABLE 817 PERU TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 818 PERU HEPATITIS IN TRAVEL VACCINE MARKET, BY DISEASE, 2022-2032 (USD THOUSAND)
TABLE 819 PERU TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 820 PERU INJECTABLE IN TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD THOUSAND)
TABLE 821 PERU TRAVEL VACCINE MARKET, BY GENDER, 2022-2032 (USD THOUSAND)
TABLE 822 PERU TRAVEL VACCINE MARKET, BY PATIENT TYPE, 2022-2032 (USD THOUSAND)
TABLE 823 PERU TRAVEL VACCINE MARKET, BY AGE GROUP, 2022-2032 (USD THOUSAND)
TABLE 824 PERU TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (USD THOUSAND)
TABLE 825 REST OF SOUTH AMERICA TRAVEL VACCINE MARKET, BY COMPOSITION, 2022-2032 (USD THOUSAND)
Liste des figures
FIGURE 1 GLOBAL TRAVEL VACCINES MARKET: SEGMENTATION
FIGURE 2 GLOBAL TRAVEL VACCINES MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL TRAVEL VACCINES MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL TRAVEL VACCINES MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL TRAVEL VACCINES MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL TRAVEL VACCINES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL TRAVEL VACCINES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL TRAVEL VACCINES MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 GLOBAL TRAVEL VACCINES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL TRAVEL VACCINES MARKET: SEGMENTATION
FIGURE 11 RISING AWARENESS ABOUT THE IMPORTANCE OF VACCINATION AMONG TRAVELERS ARE EXPECTED TO DRIVE THE GLOBAL TRAVEL VACCINES MARKET IN THE FORECAST PERIOD OF 2024 TO 2032
FIGURE 12 COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL TRAVEL VACCINES MARKET IN 2021 & 2032
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE AND THE GLOBAL TRAVEL VACCINES MARKET AND IS ALSO EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2032
FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR TRAVEL VACCINES MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2032
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL TRAVEL VACCINE MARKET
FIGURE 16 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION, 2023
FIGURE 17 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION, 2024-2032 (USD THOUSAND)
FIGURE 18 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION , CAGR (2024-2032)
FIGURE 19 GLOBAL TRAVEL VACCINE MARKET: BY COMPOSITION, LIFELINE CURVE
FIGURE 20 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, 2023
FIGURE 21 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, 2024-2032 (USD THOUSAND)
FIGURE 22 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, CAGR (2024-2032)
FIGURE 23 GLOBAL TRAVEL VACCINE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, 2023
FIGURE 25 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, 2024-2032 (USD THOUSAND)
FIGURE 26 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, CAGR (2024-2032)
FIGURE 27 GLOBAL TRAVEL VACCINE MARKET: BY CATEGORY, LIFELINE CURVE
FIGURE 28 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, 2023
FIGURE 29 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, 2024-2032 (USD THOUSAND)
FIGURE 30 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, CAGR (2024-2032)
FIGURE 31 GLOBAL TRAVEL VACCINE MARKET: BY DISEASE, LIFELINE CURVE
FIGURE 32 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 33 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2032 (USD THOUSAND)
FIGURE 34 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2032)
FIGURE 35 GLOBAL TRAVEL VACCINE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, 2023
FIGURE 37 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, 2024-2032 (USD THOUSAND)
FIGURE 38 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, CAGR (2024-2032)
FIGURE 39 GLOBAL TRAVEL VACCINE MARKET: BY GENDER, LIFELINE CURVE
FIGURE 40 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, 2023
FIGURE 41 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, 2024-2032 (USD THOUSAND)
FIGURE 42 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, CAGR (2024-2032)
FIGURE 43 GLOBAL TRAVEL VACCINE MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 44 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, 2023
FIGURE 45 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, 2024-2032 (USD THOUSAND)
FIGURE 46 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, CAGR (2024-2032)
FIGURE 47 GLOBAL TRAVEL VACCINE MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 48 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 49 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, 2024-2032 (USD THOUSAND)
FIGURE 50 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2032)
FIGURE 51 GLOBAL TRAVEL VACCINE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 52 GLOBAL TRAVEL VACCINE MARKET: SNAPSHOT (2023)
FIGURE 53 GLOBAL TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)
FIGURE 54 NORTH AMERICA TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)
FIGURE 55 EUROPE TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)
FIGURE 56 AISA-PACIFIC TRAVEL VACCINE MARKET: COMPANY SHARE 2023 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
